{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276060","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.341754+00:00","generated_at":"2026-05-16T21:21:25.474794+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kalaris Q3 net loss narrows to $11.9M; cash $77M; Phase 1a data on track for year-end","bullets":["Phase 1a SAD trial initial clinical data (safety, efficacy, PK) expected by year end 2025.","Phase 1b/2 MAD trial in nAMD enrolling up to 80 patients; initial data expected 2H 2026.","Cash, cash equivalents and ST investments $77.0M as of Sept 30, 2025; expected to fund operations into 2027.","R&D expense $9.1M (vs $36.0M in Q3 2024); net loss $11.9M (vs $38.1M).","Selected KBI Biopharma as CDMO; hired CFO Matthew Gall; opened NJ headquarters."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276060","json":"https://secwatch.observer/filing/0001193125-25-276060.json","markdown":"https://secwatch.observer/filing/0001193125-25-276060.md","text":"https://secwatch.observer/filing/0001193125-25-276060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/0001193125-25-276060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:21:25.474794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}